Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea BiotecBOM:531349 -0.69%54 EBITDA Margin % is 4.70% as of Mar. 2026, which is 64% below its 10-year median of 13.11. GuruFocus rates BOM:531349 with a GF Score™ of 54/100 and a GF Value™ of ₹359.92 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, Panacea Biotec ranks better than 70.93% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Panacea Biotec's EBITDA for the
three
months ended in Mar. 2026 was ₹78 Mil. Panacea Biotec's Revenue for the
three
months ended in Mar. 2026 was ₹1,668 Mil. Therefore, Panacea Biotec's EBITDA margin for the quarter that ended in Mar. 2026 was 4.70%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Panacea Biotec EBITDA Margin % Related Terms
Panacea Biotec EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Panacea Biotec's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531349 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Panacea Biotec's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Biotec EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panacea Biotec's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Panacea Biotec's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Biotec (BOM:531349) has a EBITDA Margin % of 4.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Panacea Biotec and its competitors. This is 64% below median its historical median of 13.11. Over the past decade, Panacea Biotec's EBITDA Margin % has ranged from 4.96 to 253.78. According to the industry distribution chart, Panacea Biotec ranks #273 out of 939 companies in the Biotechnology industry, placing it in the top 29.1%.
Is Panacea Biotec's EBITDA Margin % too high?
Panacea Biotec's current EBITDA Margin % of 4.70% is 64% below median its 10-year median of 13.11. Over the past 10 years, this metric has ranged from a low of 4.96 to a high of 253.78. Based on the distribution chart, Panacea Biotec ranks #273 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Panacea Biotec has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panacea Biotec ranks #273 out of 939 companies for EBITDA Margin %. This puts Panacea Biotec in the upper half of its industry. Historically, Panacea Biotec's own EBITDA Margin % has ranged from 4.96 to 253.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Panacea Biotec and its competitors. Panacea Biotec's current EBITDA Margin % is 4.70%, which is 64% below median its own 10-year median of 13.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹359.92, compared to a current price of ₹537.70 — trading 49.4% above its estimated fair value. The current EBITDA Margin % is 4.70%, which is 64% below median its 10-year median of 13.11. Panacea Biotec's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current EBITDA Margin % is 4.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panacea Biotec (BOM:531349) Overvalued in 2026?
Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued.
The current stock price of ₹537.70 is trading 49.4% above its estimated GF Value™ of ₹359.92.
GuruFocus considers Panacea Biotec to be Significantly Overvalued.
Key valuation signals for BOM:531349:
EBITDA Margin %: 4.70% (64% below median its 10-year median of 13.11)
GF Value™: ₹359.92 vs. price of ₹537.70 (49.4% above fair value)
No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
54GF Score
Get the complete analysis for BOM:531349
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531349 has been successfully added to your 
